HIV and ID Observations

October 7th, 2010

Post-Halladay Video Treat: Prospects for HIV Cure

For a little entertainment between playoff games — but how could anyone beat the guy in the picture? — you might want to check out this interview I did with Dan Kuritzkes about the prospects for an HIV cure. So which do you think we’ll see first — an HIV cure or a vaccine?  And I don’t mean an […]

---

July 19th, 2010

Vienna IAS: First (Really) Positive Microbicide Study

Big news from Vienna and Science, imminently: The CAPRISA 004 trial assessed effectiveness and safety of a 1% vaginal gel formulation of tenofovir, a nucleotide reverse transcriptase inhibitor, for the prevention of HIV acquisition in women. A double-blind, randomized controlled trial was conducted comparing tenofovir gel (n = 445) with placebo gel (n = 444) in sexually active, HIV-uninfected 18- to 40-year-old women in […]

---

July 12th, 2010

Neutralizing AB and How to Interpret HIV Vaccine News

Lots of attention in the news media on the recent papers in Science that elucidate the structure and function of broadly neutralizing antibody to HIV.  (Proof:  a patient asked me about it today.) For example, here’s the take by the Wall Street Journal: HIV research is undergoing a renaissance that could lead to new ways to develop […]

---

July 6th, 2010

Torrid Tuesday

Some ID/HIV-related items for a sweltering summer day: Are the AIDS Drug Assistance Programs (ADAPs) in trouble?  Certainly in some states they are, and this interview gives additional perspective.  But I wonder — how much of this is HIV-specific, and how much is just the ongoing lousy economy.  In other words, are other government-funded programs comparably stressed?  Headline:  […]

---

July 1st, 2010

RFA-AI-10-009, HIV Cure, and “Berlin Patient” Update

Interesting “RFA” (Request for Application, #RFA-AI-10-009) from Bethesda: The National Institute of Allergy and Infectious Diseases (NIAID) and the National Institute of Mental Health (NIMH), National Institutes of Health (NIH), encourage grant applications from institutions/organizations to address the problem of HIV-1 persistence in HIV-1-infected persons treated with suppressive antiretroviral drug regimens… The goal of this initiative […]

---

June 16th, 2010

Another HIV Drug Development Program Bows Out

Last month, Avexa announced that they will not be going forward with their development of the investigational NRTI apricitabine. Now Myriad says its program to develop bevirimat is closing as well. The problems with these drugs — twice daily dosing with apricitabine, formulation and mixed responses with bevirimat — are not the real story here, since arguably we […]

---

May 27th, 2010

HIV Treatment is Prevention!

The Lancet has just published a large prospective study demonstrating the protective effect of HIV treatment on the risk of viral transmission: 3381 couples were eligible for analysis … Only one of 103 genetically-linked HIV-1 transmissions was from an infected participant who had started ART, corresponding to transmission rates of 0·37 (95% CI 0·09—2·04) per 100 person-years […]

---

March 10th, 2010

The Extraordinary Power of Placebo

Just published in the journal Neurology — not typically on my radar screen — is this remarkable study comparing pregabalin to placebo for HIV-related distal sensory peripheral neuropathy. Here are the results: At endpoint, pregabalin and placebo showed substantial reductions in mean Numeric Pain Rating Scale (NPRS) score from baseline: -2.88 vs -2.63, p = 0.3941. (-snip-) […]

---

February 28th, 2010

CROI 2010 Recap: No Obvious Blockbusters, But …

Ok, I’ll admit it — I didn’t see any studies presented at CROI this year that will immediately transform HIV care on a day-to-day basis.  Nothing that will alter practice right now. Nothing like last year’s NA-ACCORD, or 2008’s surprising DAD study, or 2007’s raltegravir studies, to name a few recent examples. (All subsequently published, of course — links are to […]

---

February 19th, 2010

CROI 2011 Dates: February 27-March 3, Boston

CROI just about wrapping up — excellent, as usual.  Hope to provide some “greatest hits” shortly. But since John Mellors announced the dates of next year’s conference — and because the CROI web site can be “leisurely” in posting this information — I offer the following evidence as a public service to researchers, teachers, clinicians, and […]

---